FOR IMMEDIATE RELEASE: 2023/4/10
M3, Inc.
Edanz Inc.

M3 Acquires Scribendi Inc. in Canada
~ Strengthen Research Paper Editing Platform and Accelerate its Globalization ~

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/en; “M3” below) has announced the acquisition via its subsidiary Edanz Inc. (“Edanz” below), of Scribendi Inc. (Headquarters: Chatham, ON, Canada URL: https://www.scribendi.com and https://www.scribendi.ai; “Scribendi,” below), which provides global editing and proofreading services.

M3, Inc.
M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 320,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea, and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms. This allows the provision of services including marketing support, marketing research, and job placement support that leverage the platform’s powerful value as a media channel.

Edanz
Edanz owns a freelance platform with approximately 500 top-class scientific and medical research professionals (mainly English native speakers and Ph.D. holders), supporting the drafting and editing of research papers mainly within the medical field. As the pioneer in this field, they are a globally leading company within English editing services for research papers. Edanz caters to clients in over 120 countries, mainly in academia including The University of Tokyo and Peking University, pharmaceutical companies, and hospitals. With a repeat rate of over 80%, Edanz is highly regarded in the research community, and has supported the preparation of more than 330,000 manuscripts, as well as the development of more than 600 clinical research papers for pharmaceutical companies in Japan.

Scribendi
Scribendi owns an editing and proofreading platform with approximately 400 active freelancers and provides services to 28,000 clients annually, including the global academic community, students, researchers, authors, companies, and individuals for whom English is a second language. The company also operates on a proprietary platform and has developed its own natural language processing (NLP) AI technologies based on a dataset of more than 30 million sentences annotated by professional editors to mirror the workings of the human brain. Among other things, their technologies can automatically correct grammar, measure quality, and automate the process from receiving an order to delivery, thereby shortening lead time to only 2 hours on its platform.
Expected Synergies

Edanz and Scribendi are geographically and functionally complementary. This acquisition enables Edanz to further strengthen its capability to provide editing and publication support services to global clients promptly through Scribendi’s automated End-to-End platform. Edanz will also seek group synergies by introducing its medical writing and high-end research support services on Scribendi’s platform as well as introducing Scribendi to M3’s global platform of doctors, pharmaceutical companies, and CROs.

Scribendi Website

Scribendi Overview

Company: Scribendi Inc.
Established: 1997
Headquarters: Chatham, ON, Canada
URL: [https://www.scribendi.com](https://www.scribendi.com) and [https://www.scribendi.ai](https://www.scribendi.ai)
CEO: Koji Yamashita
Business: operation of an editing and proofreading platform